Need Help?

LifeLines-DEEP population multi-omix cohort from the noth of the Netherlands.

The LifeLines-DEEP cohort is a sub-cohort of the LifeLines cohort (167,729 participants) that employs a broad range of investigative procedures to assess the biomedical, socio-demographic, behavioral, physical and psychological factors that contribute to health and disease in the general Dutch population, (Scholtens 2015). A subset of approximately 1,500 participants also took part in LifeLines-DEEP. For these participants, additional biological materials were collected, including analysis of the gut microbiome composition. The phenotyping and processing of LifeLines-DEEP has been described in Tigchelaar (2015).

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001991 Illumina HiSeq 2000 1135
EGAD00001003453 Illumina MiSeq 1010
EGAD00001006953 -
EGAD00001006959 676
EGAD00001009268 1
Publications Citations
Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics.
BMJ Open 5: 2015 e006772
Detection of stable community structures within gut microbiota co-occurrence networks from different human populations.
PeerJ 6: 2018 e4303
Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome.
Nat Genet 50: 2018 1524-1532
Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases.
Nat Genet 51: 2019 600-605
Microbial genes and pathways in inflammatory bowel disease.
Nat Rev Microbiol 17: 2019 497-511
Relationship between gut microbiota and circulating metabolites in population-based cohorts.
Nat Commun 10: 2019 5813
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.
Nat Commun 11: 2020 362
Distribution of Bacterial α1,3-Galactosyltransferase Genes in the Human Gut Microbiome.
Front Immunol 10: 2019 3000
Binning unassembled short reads based on k-mer abundance covariance using sparse coding.
Gigascience 9: 2020 giaa028
Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD.
Gut 70: 2021 285-296
Gut microbial co-abundance networks show specificity in inflammatory bowel disease and obesity.
Nat Commun 11: 2020 4018
An association between chronic widespread pain and the gut microbiome.
Rheumatology (Oxford) 60: 2021 3727-3737
Large-scale association analyses identify host factors influencing human gut microbiome composition.
Nat Genet 53: 2021 156-165
The Composition and Metabolic Potential of the Human Small Intestinal Microbiota Within the Context of Inflammatory Bowel Disease.
J Crohns Colitis 15: 2021 1326-1338
Metabolic Phenotypes as Potential Biomarkers for Linking Gut Microbiome With Inflammatory Bowel Diseases.
Front Mol Biosci 7: 2020 603740
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
Gut 70: 2021 1287-1298
Binary Metabolic Phenotypes and Phenotype Diversity Metrics for the Functional Characterization of Microbial Communities.
Front Microbiol 12: 2021 653314
A zero inflated log-normal model for inference of sparse microbial association networks.
PLoS Comput Biol 17: 2021 e1009089
A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
Gut Microbes 13: 2021 1943288
Inulin-grown <i>Faecalibacterium prausnitzii</i> cross-feeds fructose to the human intestinal epithelium.
Gut Microbes 13: 2021 1993582
Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome.
Nat Med 28: 2022 2333-2343
Microbial vitamin production mediates dietary effects on diabetic risk.
Gut Microbes 14: 2022 2154550
Faecal metabolome and its determinants in inflammatory bowel disease.
Gut 72: 2023 1472-1485
Assessing the relationship between gut microbiota and irritable bowel syndrome: a two-sample Mendelian randomization analysis.
BMC Gastroenterol 23: 2023 150